I gave a talk Wednesday as part of an ethics series here at Duke. Here is one take on my presentation. See if you can spot the Far Side reference!
It is well accepted among health economics wonks that the lion’s share of pharmaceutical company profits come when these companies hold exclusive rights to their products. Once their blockbuster pills go “generic,” competitors enter the marketplace and profits plummet. Consider captopril, a groundbreaking heart failure medication introduced in the early 80s by Bristol-Myers Squibb under…
In a recent Health Affairs article, David Asch and I wrote about how hard it can be to stop screening aggressively for things like breast and prostate cancer even when the evidence suggests we are doing more harm than good. Well, journalist Steven Petrow has a nice piece in the Washington Post looking at the…
The below post is a response to my article Death With Dignity Should Not Be Equated With Physician Assisted Suicide by Kathryn L. Tucker, JD. My own thoughts on her response are here. In a Forbes.com oped, “Death With Dignity Should Not Be Equated With Physician Assisted Suicide, Duke University physician Peter Ubel writes: “I think it is wrong-headed to…
Interesting to see a Catholic scholar’s take on a recent issue of a pediatric journal which discussed the ethics of caring for seventy disabled newborns. I contributed an essay, and the Catholic blogger somehow concluded that most of the contributors were atheists or agnostics.
Here is the link to the post.
It is well known that Medicare expenditures threaten the financial solvency of the U.S. government. And it is pretty well agreed upon that some of our Medicare spending goes towards wasteful medical care. But which medical care is wasteful and how much is such care costing us? A study in JAMA Internal Medicine provides a…